Cell Therapies Pty Ltd

Overview

Cell Therapies manages the commercial interface for the Centre for Blood Cell Therapies (CBCT) at Peter MacCallum Cancer Centre in Melbourne, Australia.

Cell Therapies provides for-fees, cGMP cell manipulation services, clinical trial planning and execution. Our TGA license for autologous cell handling ensures compliance with TGA/FDA requirements for Phase I through Phase III trials.

We provide a responsive and cost effective service to organisations requiring access to a Good Manufacturing Practice (cGMP) licensed cell facility with a fully integrated support infrastructure capable of initiating and managing Phase I through Phase III clinical trials.

Our cell tracking capability is delivering novel information for our client’s research and clinical trials. See www.celltherapies.com.au for representative images.

Cell Therapies Fact File

  • 10 Years’ Experience in Advanced Cell and Tissue Therapies
  • TGA/FDA compliant processes and documentation. We hold our own and manage client's TGA Licenses 
  • Access to a wide range of clinical resources via the Peter Mac Cancer Centre and local or interstate collaborators
  • >350 Products Processed Annually
  • Experienced with international regulatory regimes, FDA, EMA, TGA 
  • Flexible and responsive business arrangements
  • 24/7 Communications & necessary Confidentiality Protocols
  • State of the art in-vivo cell tracking using PET, SPECT, SPECT/CT, PET/CT and 3T MRI


Number of employees
4 in corporate office, 15-20 in processing facility.

Specific focus of company
Translational medicine specialist. Contract cGMP manufacture and clinical trial planning/execution.

Core Business Definition
Fees-for-service provider at the highest possible international standard.

Competitive advantages
  • Cost effective delivery of turn key solutions for clinical trials and contract cGMP manufacturing requirements.
  • Fully integrated clinical, research and manufacturing resources able to both develop and deliver cellular therapies.
  • Experienced and committed translational medicine investigators
  • Proven ability to deliver on recruitment targets
  • Our experience in this emerging field allows us to  efficiently use our validated quality systems and deliver independent QS audits as an integral component of our deliverables.
  • Number of employees: 25+

    Main business focus/
    Listing by sector:

    • Regenerative & Stem Cells
    • Immunology
    • Bone and Cartilage
    • Clinical Trials

    Competitive Advantages

    • Cost effective delivery of turn key solutions to clinical trials and contract cGMP manufacturing requirements.
    • Fully integrated clinical, research and manufacturing resources able to both develop and deliver cellular therapies.
    • Experienced and committed translational medicine investigators
    • Proven ability to deliver on recruitment targets
    • A long-term collaboration with the Australian Red Cross Blood Service (ARCBS) allows us to very efficiently develop validated quality systems and deliver independent QS audits as an integral component of our deliverables.

    Technology/IP

    • Cell/Tissue Engineering
    • Clinical Trial Protocol development 
    • Contract cGMP Manufacturing
    • Austo and allo logistics
    • In-vivo cell tracking for bio-distribution

    Corporate Alliances/Partnerships

    • Peter MacCallum Cancer Centre
    • Cancer Trials Australia and Clinical Trials Victoria
    • CRC for Clinical Imaging
    • Mawson Instirute SA
    • HUKM Malaysia

    CBCT Trials and Cell Manipulation experience/expertise

    FieldCell typeDiseaseCategory
    Ex vivo expansion of SCBlood stem cellsBreast cancerStem cell therapy
    Monocyte-activated killer cells (MAK)MAK cellsOvarian cancerImmunotherapy
    MAK + PET imaging/trackingMAK cellsOvarian cancerImmunotherapy
    Dendritic cell therapyDendritic cellsMyelomaImmunotherapy
    Dendritic cell therapy Dendritic cellsMelanomaImmunotherapy
    Dendritic cell therapy for MUC-1 positive tumoursDendritic cellsLung cancer Breast CancerImmunotherapy
    IL-2 agonistMononuclear cellsOsteoarthritisImmunotherapy
    Chondrocyte growthChondrocytesOsteoarthritisCell replacement
    Neural therapyNeural stem cellsParkinson's diseaseCell Replacement
    Antiviral therapy for Hepatitis CDendritic cellsHepatitis CImmunotherapy
    Pancreatic therapyPancreatic cellsDiabetesCell Replacement

    Contact Details

    Contact personRaymond J Wood
    Job TitleManaging Director
    AddressGround Floor, 10 St Andrew’s Place
    City/SuburbEast Melbourne
    StateVictoria
    Operating StateNational
    Emailraywood@celltherapies.com.au
    Phone+61 3 9656 1615
    Fax+61 3 9656 1650
    Websitehttp://www.celltherapies.com.au

    Back